

SEP 24 1996

Joseph G. Och, M.S.
Radiation Safety Officer
Allegheny General Hospital
320 East North Avenue
Pittsburgh, PA 15212-9986

Dear Mr. Och:

This refers to your license amendment request. Enclosed with this letter is the amended license.

Your license has been issued in the name of an institution, please ensure that all license amendment or renewal requests are signed by a representative of the institution's management. This will assure that management has concurred with all commitments.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5093 or 5239, so that we can provide appropriate corrections and answers.

Thank you for your cooperation.

Sincerely,

ORIGINAL SIGNED BY:

Michelle R. Beardsley
Division of Nuclear Materials Safety

License No. 37-01317-04
Docket No. 030-33730
Control No. 123572

Enclosure:
Amendment No. 05

DOCUMENT NAME: R:\WPS\MLTR\3701317.04

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI				
NAME	Beardsley MB						
DATE	09/02/96	09/	/96	09/	/96	09/	/96

OFFICIAL RECORD COPY

ML 10

9611050061 960924
PDR ADOCK 03033730
C PDR

MATERIALS LICENSE

Amendment No. 05

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

OFFICIAL RECORD COPY

Licensee		In accordance with the letter dated July 2, 1996,	
1. Allegheny General Hospital		3. License Number 37-01317-04 is amended in its entirety to read as follows:	
2. 320 East North Avenue Pittsburgh, Pennsylvania 15212-9986		4. Expiration Date June 30, 2005	
		5. Docket or Reference No. 030-33730	
6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License	
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed	
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200	B. As needed	
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300	C. 500 millicuries	
D. Any byproduct material identified in 10 CFR 35.400	D. Any brachytherapy source identified in 10 CFR 35.400	D. 4 curies	
E. Phosphorus 32	E. Any	E. 3 millicuries	
F. Cesium 137	F. Sealed sources (CIS-US Models CSM-3, CSM-4, CSM-11 and CSM-41)	F. Not to exceed 65 millicuries per source and 800 millicuries total	
G. Depleted Uranium	G. Metal	G. 250 kilograms	
H. Iridium 192	H. Sealed sources (Byk Mallinckrodt Model No. CI L BV)	H. 2 sources not to exceed 10 curies each	
I. Gadolinium 153	I. Sealed sources (North American Scientific Model MED 3601)	I. Not to exceed 250 millicuries per source and 1 curie total	
J. Americium 241	J. Sealed source (Amersham Model AMC 24)	J. Not to exceed 14 millicuries per source and 30 millicuries total	
9. Authorized use			
A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.			
B. Any imaging and localization procedure approved in 10 CFR 35.200.			
C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.			
D. Any brachytherapy procedure approved in 10 CFR 35.400.			
E. <u>In vitro</u> studies.			

ML 10

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

37-01317-04

Docket or Reference Number

Q30-33730

Amendment No. 05

- F. For storage only.
- G. Shielding in a linear accelerator.
- H. One source to be used in a Nucletron Corporation Micro Selectron-HDR remote after loading brachytherapy unit for interstitial, intercavitary or intraluminal therapy and for calibrations, quality assurance checks. One source in its shipping container to be in possession of the licensee as necessary for the replacement of the irradiation device.
- I. For use in an ADAC Laboratories Model Vantage Device for patient attenuation correction during S.P.E.C.T. imaging.
- J. Use as an anatomical marker.

CONDITIONS

- 10. Licensed material may be used at the licensee's facilities located at 320 East North Avenue, Pittsburgh, Pennsylvania.
- 11. The Radiation Safety Officer for this license is Joseph G. Och, M.S.
- 12. The Medical Physicist for this license is Andrew Wu, Ph.D.
- 13. Licensed material is authorized only for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized Users

Material and Use

Mustafa Adatepe, M.D.

35.100; 35.200; 35.300

Steven A. Burton, M.D.

35.400

Iridium-192 in a brachytherapy remote afterloader for the treatment of humans
Cesium 137
Depleted Uranium

Alexander Chen, M.D.

35.400

Iridium-192 in a brachytherapy remote afterloader for the treatment of humans
Cesium 137
Depleted Uranium

Angel R. Flores, M.D.

35.100; 35.200 for cardiovascular clinical procedures; Gadolinium 153 for patient attenuation correction during S.P.E.C.T. imaging; Americium 241 sealed source

Philip Dunbar Nicol, M.D.

35.100; 35.200 for cardiovascular clinical procedures; Gadolinium 153 for patient attenuation correction during S.P.E.C.T. imaging; Americium 241 sealed source

Gilbert Isaacs, M.D.

35.100; 35.200; 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

37-01317-04

Docket or Reference Number

030-33730

Amendment No. 05

Shalom Kalnicki, M.D.

35.400

Iridium-192 in a brachytherapy remote afterloader for the treatment of humans
Cesium 137
Depleted Uranium

Jeanne Thomas, Ph.D.

Phosphorus 32

Andrew Wu, Ph.D.

Iridium-192 in a brachytherapy remote afterloader for calibrations and quality assurance testing

Douglas S. Schulman, M.D.

35.100; 35.200 for cardiovascular clinical procedures

14. Notwithstanding the requirements of 10 CFR 35.92(a), the licensee may hold any radioactive material authorized by this license with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash, provided the licensee stores the material for decay in accordance with all other requirements of 10 CFR 35.92.
15. Notwithstanding the requirements of 10 CFR 35.400(d) and (g), the licensee may use iridium-192 as seeds encased in nylon ribbon and palladium-103 as a sealed source in seeds for topical, interstitial, and intracavitary treatment of cancer. The licensee may deviate from the manufacturer's radiation safety and handling instructions to the extent that the instructions are not applicable to the type of use proposed by the licensee.
16. A. Access to the treatment room housing each high dose rate remote afterloading brachytherapy unit shall be controlled by a door at each entrance.
- B. Each entrance to the treatment room shall be equipped with an electrical interlock system that will cause the source to return to the shielded position immediately upon opening of the entrance door. The interlock system shall be connected in such a manner that the source cannot be placed in the irradiation position until the entrance door is closed and the source "on-off" control is reset at the control panel.
- C. Electrical interlocks on each entrance door to the treatment room shall be tested for proper operation at least once each day of use.
- D. In the event of malfunction of the door interlock, the unit shall be locked in the "off" position and not used, except as may be necessary for repair or replacement of the interlock system, until the interlock system is shown to be functioning properly.
17. Prior to initiation of a treatment program, and subsequent to each source exchange for each high dose rate remote afterloading brachytherapy unit, a radiation survey shall be made of:
 - A. The source housing, with the source in the shielded position. The maximum radiation levels at 10 centimeters from the surface of the main source safe shall not exceed 1 millirem per hour.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

37-01317-04

Docket or Reference Number

030-33730

Amendment No. 05

- B. All areas adjacent to the treatment room with the source in the exposed position. The survey shall clearly establish:
- (1) That radiation doses to occupationally exposed individuals do not exceed the limits specified in 10 CFR 20.1201(a), 20.1207 and 20.1208.
 - (2) That radiation doses to individual members of the public do not exceed the limits specified in 10 CFR 20.1301(a).
18. The following shall be performed only by persons specifically authorized by the Commission or an Agreement State to perform such service:
- A. Installation, and replacement of the sealed sources contained in each high dose rate remote afterloading brachytherapy unit.
 - B. Maintenance or repair operations on any high dose rate remote afterloading brachytherapy unit and associated equipment involving work on the source safe, the source driving unit, or other mechanism that could expose the source, reduce the shielding around the source, or compromise the safety of the unit and result in increased radiation levels.
19. In lieu of the source inventory described in 10 CFR 35.406, the licensee shall:
- A. Promptly determine that all sources have returned to the safe, shielded position at the conclusion of each high dose remote brachytherapy procedure.
 - B. Promptly make a survey of the area of use to confirm that no sources have been misplaced.
 - C. Make a record of the survey including survey instrument used, dose rate, time, date and name of the individual making the survey.
 - D. Retain the record of the survey in lieu of the record required in 10 CFR 35.406(d).
20. In lieu of 10 CFR 35.404(a), immediately after retracting the source from the patient into its shielded position in the remote afterloading device, radiation survey shall be made of the patient and the remote afterloading device with a portable radiation detection survey instrument to confirm that the source has been removed from the patient. Records of the survey shall be maintained in lieu of the record required in 10 CFR 35.404(b).
21. A. Sealed sources and detector cells containing licensed material shall be tested for leakage and/or contamination at intervals not to exceed six months or at such other intervals as are specified by the certificate of registration referred to in 10 CFR 32.210, not to exceed three years.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed three months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number

37-01317-04

Docket or Reference Number

030-33730

Amendment No. 05

detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

E. Sealed sources and detector cells need not be leak tested if:

- (i) they contain only hydrogen-3; or
- (ii) they contain only a radioactive gas; or
- (iii) the half-life of the isotope is 30 days or less; or
- (iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or
- (v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transfer to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source or detector cell shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within five days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region I, ATTN: Chief, Nuclear Materials Safety Branch, 475 Allendale Road, King of Prussia, Pennsylvania 19406. The report shall specify the source or detector cell involved, the test results, and corrective action taken.

G. The licensee is authorized to collect leak test samples for analysis by the licensee. Alternatively, tests for leakage and/or contamination may be performed by persons specifically licensed by the Commission or an Agreement State to perform such services.

22. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
23. The licensee shall conduct a physical inventory every three months to account for all sealed sources and devices containing licensed material received and possessed pursuant to 10 CFR 35.59, 35.400 and 35.500 and every six months for all other sealed sources and devices.
24. The licensee shall not acquire licensed material in a sealed source or device unless the source or device has been registered with the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or equivalent regulations of an Agreement State.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

37-01317-04

Docket or Reference Number

030-33730


Amendment No. 05

25. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
26. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material at a single location to quantities below the limits specified in 10 CFR 30.72 which require consideration of the need for an emergency plan for responding to a release of licensed material.
27. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
28. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Letter dated January 20, 1995
 - B. Letter dated May 8, 1995
 - C. Letter dated July 21, 1995
 - D. Letter dated November 3, 1995 except Attachment I
 - E. Letter dated December 18, 1995
 - F. Letter dated March 25, 1996
 - G. Letter dated May 2, 1996
 - H. Letter dated July 2, 1996

For the U.S. Nuclear Regulatory Commission

Date SEP 24 1996

Original Signed By:
Michelle Beardsley
Nuclear Materials Safety Branch
Region I
King of Prussia, Pennsylvania 19406



ALLEGHENY GENERAL HOSPITAL

MS16

J-1

320 East North Avenue
Pittsburgh, Pennsylvania 15212-4772
412-359 3131

September 17, 1996

Michelle Beardsley
USNRC Region 1
475 Allendale Road
King of Prussia, PA 19406

030-33730

Dear Ms. Beardsley,

Attached is the additional information you requested for the most recent amendments to NRC
License #37-01317-04, Mail Control Number 123572.

Should you have any questions please contact me at 412-359-6864.

Sincerely,

A handwritten signature in cursive script, appearing to read 'Joseph G. Och'.

Joseph G. Och, M.S.
Radiation Safety Officer

JGO/ir

enclosures (8)

OFFICIAL RECORD COPY

ML 10


123572

VHA

Member of Voluntary Hospitals of America, Inc.

FAX REC'D

SEP 17 1996



320 East North Avenue
Pittsburgh, PA 15212-4772
Telephone (412) 359-3131

To Whom it May Concern;


This letter is to affirm that Dr. Douglas S. Schulman gained clinical experience at Allegheny General Hospital in nuclear cardiology. The preceptorship began September 1, 1995 and continued through April 30, 1996. During this period, the doctor actively participated in the following number of procedures:

1000 Thallium-201 stress imaging procedures-----	350 hours
1000 Thallium-201 rest imaging procedures-----	150 hours
250 PYP/RBC multi-gated acquisition rest procedures---	40 hours
50 PYP/RBC multi-gated acquisition stress procedures---	20 hours
300 ejection fraction calculation procedures-----	25 hours
300 wall motion evaluation studies-----	40 hours

During this time, the doctor also acquired 500 hours experience in health physics, radiopharmaceutical preparation, technical and administrative procedures of our facility, as well as general operations as stipulated by our license conditions. The doctor also gained experience in the preparation of radiopharmaceutical kits during this period, and eluted the ^{99m}Tc ^{99}Mo generator.

The number of hours of nuclear cardiology clinical and work experience accrued during this period total 1125 hours.

Sincerely,


Angel Flores, MD
9/16/96

Material License Number:
37-01317-04

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


DOUGLAS S. SCHULMAN, M.D.

has successfully completed the didactic program

MEDICAL RADIATION INSTRUMENTATION

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon participant request

13 March 1996

Date Class Commenced


Authorized Signature

191185
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 — 800-548-4024

1132 INME 8/94

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


DOUGLAS S. SCHULMAN, M.D.

has successfully completed the didactic program

PRINCIPLES OF RADIATION PHYSICS

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*Additional documentation will be provided to Regulatory Agencies upon participant request

9 March 1996

Date Class Commenced


Authorized Signature

191194
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 — 800-548-4024

1132 INME 8/94

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


DOUGLAS S. SCHULMAN, M.D.

has successfully completed the didactic program

MEDICAL RADIATION PROTECTION

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*Additional documentation will be provided to Regulatory Agencies upon participant request

10 February 1996

Date Class Commenced

Authorized Signature

191065
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 — 800-548-4024

1132 INME 8/94

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

NUCLEAR MEDICAL EDUCATION PROGRAM

Affidavit of Academic Completion and Competency

This document is to attest that


DOUGLAS S. SCHULMAN, M.D.

has successfully completed the didactic program

RADIOPHARMACEUTICALS AND CHEMISTRY

and has provided evidence of attendance in this program and evidence of achieving the objectives of this program through examination.

This program provides the following levels of accomplishment:



- 50 Didactic Instructional Hours (DIH)
(In compliance with 10CFR35)
- 5 Continuing Education Units (CEU)
- 50 Continuing Medical Education (CME)
- 50 Technical/Professional Credit specified by the
American Pharmaceutical Association and the
American Association of Health Physicists*

*additional documentation will be provided to Regulatory Agencies upon participant request

14 February 1996
Date Class Commenced


Authorized Signature

191101
Affidavit of Competency

INSTITUTE FOR NUCLEAR MEDICAL EDUCATION

5171 Eldorado Springs Drive, Boulder, CO 80303 — 800-548-4024

1132 INME 8/94

Certified, Approved and Regulated by the Division of Private Occupational Schools, Department of Higher Education in Colorado. Validated by the Accrediting Commission of the Accrediting Council for Continuing Education Training, a national accrediting agency listed by the US Secretary of Education. Validated by the American Council on Education, recognized by the American Association for Collegiate Registrars, Council on Post-Secondary Education.

ALLEGHENY GENERAL HOSPITAL
INTERDEPARTMENTAL MEMORANDUM
MEDICAL PHYSICS DEPARTMENT

DATE: August 1, 1996

TO: File

FROM: Joe Rizzi



SUBJECT: Final Contamination and Radiation Survey at the Wexford Site

The Wexford Site was a Nuclear Cardiology imaging facility where procedures such as stress test and MUGA scans were performed using Tc-99m and Tl-201. Throughout the time the facility was operated daily exposure surveys and weekly contamination surveys were performed and for each no excess contamination was found at the facility.

Operation at the site was terminated and a final exposure and contamination survey was performed on July 24, 1996. A thorough survey was performed and, as expected, no exposure levels above background or contamination was found.

FINAL SURVEYALLEGHENY GENERAL HOSPITAL
RADIOACTIVE MATERIAL
CONTAMINATION SURVEYSURVEY DATE 7/24/96
LOCATION - NUCLEAR CARDIOLOGY - WEXFORD


COUNTING INSTRUMENT:


✓ CAPRAC S/N 000188
OTHER _____ S/N _____BACKGROUND 451 CPMMDA 127 DPMSURVEYOR DK R DATE 7/24/96COMMENTS C.E. = 27% 1765 = STANDARDC.F. = 1.25 DPA 170W 9427 COTA = ALL NUMERICAL DATA UNDER MIN. D.A. 1.0

A

LOCATION	$\frac{\text{cpm}}{100 \text{ cm}^2}$	TRIGGER LEVEL $\frac{\text{cpm}}{100 \text{ cm}^2}$
1 HALL	0	200
2 RAD WASTE	0	500
3 HOT LAB	0	500
4 EXERCISE ROOM	0	200
5 EXERCISE ROOM	0	200
6 IMAGING ROOM	0	200
7 HALL	0	200
8 WAITING AREA	0	200
9 BATHROOM	0	200
10 DRESSING ROOM	0	200

* CONTACT RSO WHEN TRIGGER LEVEL IS EXCEEDED





ALLEGHENY GENERAL HOSPITAL

320 East North Avenue
Pittsburgh, Pennsylvania 15212-9986
412-359-3131

US Nuclear Regulatory Commission
Region I
Michelle Beardsley
475 Allendale Road
King of Prussia, PA 19406-1415

37-01317-04

Control Number 12357²~~7~~ map

Dear Ms. Beardsley,

As per our conversation on August 28, 1996 I have attached NRC Form 313M suppl. A & B for Douglas S. Schulman, M.D. (Control Number 123572).

Please contact me at 412 359-8297 if you need additional information.

Sincerely,

Joseph Rizzi
Assistant Radiation Safety Officer

enclosures (3)

OFFICIAL RECORD COPY

ML 10

123572

VHA.

Member of Voluntary Hospitals of America, Inc.

FAX REC'D

AUG 30 1996

FORM NRC-313M-SUPPLEMENT A

U.S. NUCLEAR REGULATORY COMMISSION

(8-78)

**TRAINING AND EXPERIENCE
AUTHORIZED USER OR RADIATION SAFETY OFFICER**

1. NAME OF AUTHORIZED USER OR RADIATION SAFETY OFFICER <i>Douglas S. Schulman</i>		2. STATE OR TERRITORY IN WHICH LICENSED TO PRACTICE MEDICINE <i>PA</i>		
3. CERTIFICATION				
SPECIALTY BOARD <i>A</i>	CATEGORY <i>B</i>	MONTH AND YEAR CERTIFIED <i>C</i>		
<i>Internal medicine</i>		<i>9/84</i>		
<i>Cardiovascular Disease</i>		<i>11/87</i>		
4. TRAINING RECEIVED IN BASIC RADIOISOTOPE HANDLING TECHNIQUES				
FIELD OF TRAINING <i>A</i>	LOCATION AND DATE(S) OF TRAINING <i>B</i>	TYPE AND LENGTH OF TRAINING		
		LECTURE/ LABORATORY COURSES (Hours) <i>C</i>	SUPERVISED LABORATORY EXPERIENCE (Hours) <i>D</i>	
<i>B. RADIATION PHYSICS AND INSTRUMENTATION</i>	<i>Orlando, Florida 2/96 Oakbrook, Illinois 3/92 (Institute for Nuclear Med. Education)</i>	<i>100</i>		
<i>D. RADIATION PROTECTION</i>	<i>"</i>	<i>30</i>		
<i>C. MATHEMATICS PERTAINING TO THE USE AND MEASUREMENT OF RADIOACTIVITY</i>	<i>"</i>	<i>10</i>		
<i>E. RADIATION BIOLOGY</i>	<i>"</i>	<i>20</i>		
<i>F. RADIOPHARMACEUTICAL CHEMISTRY</i>	<i>"</i>	<i>30</i>		
5. EXPERIENCE WITH RADIATION. (Actual use of Radioisotopes or Equivalent Experience)				
ISOTOPE	MAXIMUM AMOUNT	WHERE EXPERIENCE WAS GAINED	DURATION OF EXPERIENCE	TYPE OF USE
<i>Tl-201</i>	<i>10 mCi</i>	<i>Allegheny General</i>	<i>9/95 - 4/96</i>	<i>Clinical</i>
<i>Tc-99m</i>	<i>30 mCi</i>	<i>Allegheny General</i>	<i>9/95 - 4/96</i>	<i>Clinical</i>

FORM NRC-313M Supplement A
(8-78)

FORM NRC-313M SUPPLEMENT B
(8-78)

U. S. NUCLEAR REGULATORY COMMISSION

PRECEPTOR STATEMENT

Supplement B must be completed by the applicant physician's preceptor. If more than one preceptor is necessary to document experience, obtain a separate statement from each.

1. APPLICANT PHYSICIAN'S NAME AND ADDRESS		KEY TO COLUMN C
FULL NAME Douglas S. Schulman		PERSONAL PARTICIPATION SHOULD CONSIST OF: 1-Supervised examination of patients to determine the suitability for radionuclide diagnosis and/or treatment and recommendation for prescribed dosage. 2-Collaboration in dose calibration and actual administration of dose to the patient including calculation of the radiation dose, related measurements and plotting of data. 3-Adequate period of training to enable physician to manage radiocost patients and follow patients through diagnosis and/or course of treatment.
STREET ADDRESS 612 S. Linden Avenue		
CITY Pittsburgh	STATE PA	
ZIP CODE 15208		

2. CLINICAL TRAINING AND EXPERIENCE OF ABOVE NAMED PHYSICIAN

ISOTOPE A	CONDITIONS DIAGNOSED OR TREATED B	NUMBER OF CASES INVOLVING PERSONAL PARTICIPATION C	COMMENTS (Additional information or comments may be submitted in duplicate on separate sheets.) D
I-131 or I-125	DIAGNOSIS OF THYROID FUNCTION		
	DETERMINATION OF BLOOD AND BLOOD PLASMA VOLUME		
	LIVER FUNCTION STUDIES		
	FAT ABSORPTION STUDIES		
	KIDNEY FUNCTION STUDIES		
	IN VITRO STUDIES		
OTHER			
I-125	DETECTION OF THROMBOSIS		
I-131	THYROID IMAGING		
P-32	EYE TUMOR LOCALIZATION		
Sr-75	PANCREAS IMAGING		
Yb-169	GISTERNOGRAPHY		
Kr-133	BLOOD FLOW STUDIES AND PULMONARY FUNCTION STUDIES		
OTHER			
Tc-99m	BRAIN IMAGING		
	CARDIAC IMAGING	1000	
	THYROID IMAGING		
	SALIVARY GLAND IMAGING		
	BLOOD POOL IMAGING	250	
	PLACENTA LOCALIZATION		
	LIVER AND SPLEEN IMAGING		
	LUNG IMAGING		
	BONE IMAGING		
OTHER			

FORM NRC-313M-SUPPLEMENT B
(8-78)

This is to acknowledge the receipt of your letter/application dated

7/2/96, and to inform you that the initial processing which includes an administrative review has been performed.

- ☐ There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.
- ☒ Please provide to this office within 30 days of your receipt of this card the missing enclosures (NRC Form 313M Suppl. A & B for Douglas S. Schulman, M.D.).

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 123572.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.

NRC FORM 532 (R)
(6-98)

Sincerely,
Licensing Assistance Team Leader

OFFICIAL RECORD COPY

ML 10

July 2, 1996

Joanne Stambaugh
USNRC Region 1
475 Allendale Road
King of Prussia, PA 19406

030-33730

Dear Ms. Stambaugh,


Allegheny General Hospital requests the following amendments to NRC License #37-01317-04.

1. Add Douglas S. Schulman, M.D. as an authorized user for items, 6. A., by-product material prescribed in Part 35.100 and for item 6. B., by-product material prescribed in Part 35.200. Enclosed are forms NRC-313M supplements A and B.
2. Delete Kristine E. Kokeny, M.D. as an authorized user from the license.
3. Remove Wexford Nuclear Cardiology at Wexford Professional Building No.2, Suite 201, 1176 Perry Highway, Wexford, PA 15090 as a site from our licence.

Enclosed is the licence amendment fee of \$430.00.

Should you have any questions please contact me at 412-359-6864.

Sincerely,



Joseph G. Och, M.S.
Radiation Safety Officer

JGO/jr

enclosures (2)

OFFICIAL RECORD COPY

ML 10

123572

AUG 16 1996

LICENSE FEE REQUIREMENTS

LICENSE FEE AND DEBT COLLECTION BRANCH
DIVISION OF ACCOUNTING AND FINANCE
OFFICE OF THE CONTROLLER
U.S. NUCLEAR REGULATORY COMMISSION
WASHINGTON, DC 20555-0001ALLEGHENY GENERAL HOSPITAL
ATTN: JOSEPH G. OCH, M.S.
RADIATION SAFETY OFFICER
320 EAST NORTH AVENUE
PITTSBURGH, PENNSYLVANIA 15212-4472

TYPE OF ACTION

- ☐ NEW LICENSE
☐ RENEWAL OF LICENSE
☒ AMENDMENT TO LICENSE

REQUESTED DATE

7-2-96

LICENSE NUMBER

37-01317-04

CONTROL NUMBER

123572

I. APPLICATION FEE DUE

Your request for a licensing action is subject to the fee(s) in the category(ies) noted below in accordance with Section 170.31 of the enclosed Federal Register notice. Payment of the fee is required prior to the issuance of the license, renewal, or amendment.

FEE CATEGORY	APPLICATION	RENEWAL	AMENDMENT
7C	\$	\$	\$ 440.00
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$
	\$	\$	\$

FEE(s) DUE	\$	440.00
PAYMENT RECEIVED	\$	430.00
AMOUNT DUE	\$	10.00

☐ Your request was received without the prescribed application fee.

☒ We received your Check No. 1010055894 in the amount of \$ 430.00. Payment of the additional fee noted above is required.

☐ Your request will increase the scope of your license program. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Your license expired prior to the receipt of your application for renewal. Therefore, your request is subject to the application fee(s) noted above. Refer to Section 170.31 and Footnote 1(a).

MAKE PAYMENT OF THE FEE(S) TO THE U.S. NUCLEAR REGULATORY COMMISSION AND MAIL THE PAYMENT TO THE ADDRESS LISTED AT THE TOP OF THIS FORM. IF WE DO NOT RECEIVE A REPLY FROM YOU WITHIN 30 CALENDAR DAYS FROM THE DATE LISTED BELOW, WE SHALL ASSUME THAT YOU DO NOT WISH TO PURSUE YOUR APPLICATION AND WILL VOID THIS ACTION.

SIGNATURE - LICENSE FEE ANALYST

LFDCB

LFDCB

SHIRLEY CRITCHFIELD

9/3/96

II. FEE NOT REQUIRED

☐ Enclosed is Check No. _____ which accompanied your request. The fee is not required because:

☐ We received your Check No. _____ in payment of the fee.

☐ The Licensing staff has informed us that your request is to be considered as a continuation of your request dated _____, Control No. _____.

☐ Your request was combined, prior to review, with your _____ request, Control No. _____.

III. CHECK RETURNED

☐ Enclosed is Check No. _____ which was returned to us by the bank for:

- ☐ INSUFFICIENT FUNDS
☐ ACCOUNT CLOSED
☐ OTHER

MAIL THE REPLACEMENT CHECK TO THE ADDRESS LISTED AT THE TOP OF THIS FORM AND REFERENCE THE ABOVE CONTROL NUMBER.

IV. LICENSE ISSUED WITHOUT THE REQUIRED FEE

☐ License No. _____, Amendment No. _____, issued on _____ was issued without the required fee being collected. The fee required is noted in Section I of this form.

☐ The scope of your licensed program was increased. Therefore, your request is subject to the application fee(s) noted in Section I of this form. Refer to Section 170.31 and Footnote 1(d)(2).

☐ Because of the urgency of your request, the license was issued without remittance of the prescribed fee noted in Section I of this form.

Distribution:

Pending Fee File

LFARB R/F (2)

OC/DAF/RP
OC/DAF/SF(LF-3 2 7)
Region I

DATE

Sept. 4/1996

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

LICENSE FEE TRANSMITTAL

A. REGION I

1. APPLICATION ATTACHED

APPLICANT/LICENSEE: ALLEGHENY GENERAL HOSPITAL
RECEIVED DATE: 960816
DOCKET NO: 3033730
CONTROL NO.: 123572
LICENSE NO.: 37-01317-04
ACTION TYPE: AMENDMENT

2. FEE ATTACHED

AMOUNT: \$430.00
CHECK NO.: 1010055894

3. COMMENTS

SIGNED
DATE

Rachel Simon
8/17/96

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED)

1. FEE CATEGORY AND AMOUNT: 7C

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:

AMENDMENT _____
RENEWAL _____
LICENSE _____

3. OTHER _____

SIGNED
DATE

9/24/96
Mike called
regarding expedite
L. Cohen license
to get commitment
\$40.00 invoice check today
license pending check today
07 for 9/24/96

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02230
STATUS CODE: 0
FEE CATEGORY: 7C 28
EXP. DATE: 20050630
FEE COMMENTS: _____
DECOM FIN ASSUR REQD: N

1996 AUG 22 PM 8:22

Log	<u>Aug 13 I</u>
Remitter	_____
Check No.	<u>1010055894/2050078388</u>
Amount	<u>\$430.00</u>
Fee Category	<u>7C 28</u>
Type of Fee	<u>Amend</u>
Date Check Rec'd	<u>8/22/96</u>
Date Completed	<u>10/16/96</u>
By:	<u>AS</u>

LICENSED
OVERPAID
BY 10. AR
LEFT TRUNK
NO REFUND
BY 10. AR
LESS ARG
GIVEN: 60